Tiziana Life Sciences

About:

Tiziana Life Sciences is a UK biotechnology company.

Website: http://www.tizianalifesciences.com/

Top Investors: National Institutes of Health, The ALS Association

Description:

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently completing phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy and has filed an IND to enroll patients in an exploratory trial in Hepatic Cellular Carcinoma (HCC).

Total Funding Amount:

$12.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

1998-02-11

Founders:

Number of Employees:

1-10

Last Funding Date:

2024-10-31

IPO Status:

Public

Industries:

© 2025 bioDAO.ai